Crossject SA
PAR:ALCJ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (7.2), the stock would be worth €-0.73 (136% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -19.8 | €2 |
0%
|
| Industry Average | 7.2 | €-0.73 |
-136%
|
| Country Average | 7.3 | €-0.73 |
-137%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
€103.8m
|
/ |
Jul 2025
€-5.3m
|
= |
|
|
€103.8m
|
/ |
Dec 2025
€10.5m
|
= |
|
|
€103.8m
|
/ |
Dec 2026
€25.5m
|
= |
|
|
€103.8m
|
/ |
Dec 2027
€28.1m
|
= |
|
|
€103.8m
|
/ |
Dec 2028
€54.4m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| FR |
|
Crossject SA
PAR:ALCJ
|
101.3m EUR | -19.8 | -9 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
62B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.6T JPY | 27.9 | 38.5 | |
| CH |
|
Alcon AG
SIX:ALC
|
29.4B CHF | 14.5 | 37.7 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
95.4B DKK | 12.7 | 24 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
14B USD | 14.9 | 34.1 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.5B GBP | 11.9 | 34.3 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.7B USD | 16.9 | -15.7 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
880.1B JPY | 23.5 | 49.8 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8T KRW | -81.4 | -36.4 | |
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.4B USD | 14.7 | 22.9 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 5.3 |
| Median | 7.3 |
| 70th Percentile | 11.7 |
| Max | 1 862.3 |
Other Multiples
Crossject SA
Glance View
Crossject SA manufactures and markets needle-free injection system. The company is headquartered in Dijon, Bourgogne-Franche-Comte. The firm specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The firm's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject’s first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The firm has industrial partnerships with Hirtenberger and Recipharm.
